Sort by
Keyphrases
Anti-respiratory Syncytial Virus
100%
Preclinical Assessment
100%
Diferuloylmethane
100%
Respiratory Syncytial Virus
62%
Respiratory Syncytial Virus Infection
37%
Infant Patients
25%
Young children
25%
Hospitalization
25%
Inflammation
12%
Virus Replication
12%
Pediatric Population
12%
Preclinical Data
12%
Estimated Cost
12%
Australia
12%
Palivizumab
12%
Low-side
12%
Hospital Admission
12%
Preclinical Efficacy
12%
In Vivo Model
12%
Virus Diseases
12%
High-risk Infants
12%
Antiviral Activity
12%
Optimal Potentials
12%
Virus Activity
12%
Health Technology
12%
Bioavailable
12%
Most Common Cause
12%
Phase II Clinical Trial
12%
Lower Respiratory Tract Infection
12%
Efficacy Study
12%
Efficacy Data
12%
Anti-inflammatory Effect
12%
All Pediatric
12%
Host Inflammatory Response
12%
Western Australia
12%
Data Required
12%
Ribavirin
12%
Oral Bioavailability
12%
Human Trials
12%
Pharmacology, Toxicology and Pharmaceutical Science
Human respiratory syncytial virus
100%
Curcumin
80%
Respiratory Syncytial Virus Infection
30%
Inflammation
20%
Clinical Trial
20%
Side Effect
20%
Antivirus Agent
10%
Efficacy Study
10%
Bioavailability
10%
Infection
10%
Palivizumab
10%
Lower Respiratory Tract Infection
10%
Ribavirin
10%
Antiinflammatory Activity
10%
Diseases
10%
Biochemistry, Genetics and Molecular Biology
Human respiratory syncytial virus
100%
Clinical Trial
15%
Animal Model
15%
Palivizumab
7%
Efficacy Study
7%
Antiinflammatory Activity
7%
Ribavirin
7%